ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,180.74
1.03%
US Tech 100
17,599.60
1.04%
Dow Jones
38,852.27
0.46%
Brent Oil
83.445
-0.04%
Bitcoin
63,729.75
0.89%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. IO Biotech Inc (IOBT) Quote

IO Biotech Inc

IO Biotech Inc (IOBT)

NASDAQ
1.49
0.01
(0.68%)
Closed May 06 4:00PM
Delayed by 15 minutes
1.49
0.00
(0.00%)
After Hours: 5:59PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.49
Bid
1.43
Ask
1.80
Volume
44,782
1.45 Day's Range 1.55
0.8163 52 Week Range 2.29
Market Cap
97.504M
Previous Close
1.48
Open
1.53
Last Trade
156
@
1.49
(formt)
Last Trade Time
Financial Volume
$ 67,453
VWAP
1.5063
Average Volume (3m)
129,176
Shares Outstanding
65,880,914
Dividend Yield
-
PE Ratio
-1.13
Earnings Per Share (EPS)
-1.31
Revenue
-
Net Profit
-86.08M

About IO Biotech Inc

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced imm... IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.iobiotech.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
IO Biotech Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IOBT. The last closing price for IO Biotech was $1.48. Over the last year, IO Biotech shares have traded in a share price range of $ 0.8163 to $ 2.29.

IO Biotech currently has 65,880,914 shares outstanding. The market capitalization of IO Biotech is $97.50 million. IO Biotech has a price to earnings ratio (PE ratio) of -1.13.

IOBT Latest News

More News

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

April 24 2024
GlobeNewswire Inc.

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

April 15 2024
GlobeNewswire Inc.

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

April 09 2024
GlobeNewswire Inc.

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

April 05 2024
GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans

March 11 2024
Edgar (US Regulatory)

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a...

March 06 2024
GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

March 05 2024
Edgar (US Regulatory)

Form 8-K - Current report

March 05 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.04-2.614379084971.531.611.42581431.51437928CS
4-0.19-11.30952380951.681.681.4811621.51235412CS
12-0.3-16.75977653631.791.851.41291761.60748428CS
260.5456.84210526320.952.0980.83131166191.59501378CS
52-0.73-32.88288288292.222.290.81631461561.61345217CS
156-14.51-90.68751617.880.8163988003.46943006CS
260-14.51-90.68751617.880.8163988003.46943006CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUVOHoldco Nuvo Group DG Ltd
$ 5.2108
(155.43%)
43.44M
XBPXBP Europe Holdings Inc
$ 3.4999
(65.09%)
55.73M
PLTNPlutoniam Acquisition Corporation
$ 9.40
(56.41%)
1.43M
PRFTPerficient Inc
$ 73.27
(52.30%)
11.68M
NRXPNRX Pharmaceuticals Inc
$ 3.05
(45.24%)
9.31M
LYRALyra Therapeutics Inc
$ 0.519
(-87.12%)
108.65M
GLYCGlycoMimetics Inc
$ 0.3165
(-82.70%)
40.92M
EYPTEyePoint Pharmaceuticals Inc
$ 11.15
(-43.52%)
9.65M
LGHLWLion Group Holding Ltd
$ 0.0047
(-32.86%)
100.74k
MMATMeta Materials Inc
$ 2.44
(-27.16%)
580.58k
LYRALyra Therapeutics Inc
$ 0.519
(-87.12%)
108.65M
SQQQProShares UltraPro Short QQQ
$ 10.70
(-3.43%)
94.71M
NKLANikola Corporation
$ 0.6497
(-1.19%)
89.11M
MARAMarathon Digital Holdings Inc
$ 20.695
(18.12%)
87.05M
TSLATesla Inc
$ 184.76
(1.97%)
84.41M

IOBT Discussion

View Posts
axelvento axelvento 2 days ago
Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee
Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors
Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025

https://www.biopharmcatalyst.com/company/IOBT/news/190095
👍️0
axelvento axelvento 2 weeks ago
https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Abstract-Accepted-for-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspx
👍️0
axelvento axelvento 4 weeks ago
IO Biotech was founded in 2014 and just 10 years into the journey we are in a pivotal phase III trial I think that’s quite fast
👍️0
axelvento axelvento 4 weeks ago
next catalyst-In November 2023, the company completed enrollment of 380 patients in its pivotal Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in advanced melanoma. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS). The PFS analysis is event-driven and will be conducted when 226 events have occurred in the trial, which the company estimates will take place in the second half of 2025. Additionally, a planned interim analysis of overall response rate (ORR) will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024.
👍️0
Monksdream Monksdream 2 months ago
IOBT under $2
👍️0
Monksdream Monksdream 3 months ago
IOBT under $2
👍️0
Monksdream Monksdream 6 months ago
IOBT new 52 week low
👍️0
Monksdream Monksdream 7 months ago
IOBT new 52 week low
👍️0
Monksdream Monksdream 7 months ago
IOBT ubder $2
👍️0
AJ Freely AJ Freely 9 months ago
$IOBT - 👆Up 1.8% Pre-Market/ Current Price $2.00
Announces $75 Million Private Placement Financing
👍️0
The Night Stalker The Night Stalker 11 months ago
nice
👍️0
kzivann kzivann 11 months ago
Extremely heavy volume on good news. PPS down . Lower this AM. Watching

IOBT
👍️0
Phosphene Phosphene 2 years ago
IO Biotech’s (NASDAQ:IOBT ) lock-up period is set to end on Wednesday, May 4th.

https://www.defenseworld.net/2022/04/27/io-biotech-inc-s-lock-up-period-set-to-end-on-may-4th-nasdaqiobt.html
👍️0
conix conix 2 years ago
Bitoechs are waking up ---like they did last year.

I shopped for a number of sold out biotechs in December and picked and chose a number of sold out biotechs.

IOBT --I missed. But there are legs here. I have done well on four of my picks. Still waiting on two.

Time will tell.
👍️0
Phosphene Phosphene 2 years ago
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor types

https://www.globenewswire.com/news-release/2021/12/06/2346557/0/en/IO-Biotech-Announces-Third-Clinical-Collaboration-with-Merck-to-Evaluate-IO102-IO103-in-Combination-With-KEYTRUDA-pembrolizumab-as-First-Line-Treatment-in-a-Phase-2-Multi-Arm-Baske.html

👍️0
Eggplant Eggplant 2 years ago
What happened? IPO at $14/sh four weeks ago, and the stock has nearly folded in half. No news, and the only sellers should be the IPO buyers, right? Mystery.
👍️0
Work Harder Work Harder 2 years ago
I was right on the 7

for now

Yu tell wifeie

I appreciate her time

:}
👍️0
Phosphene Phosphene 2 years ago
Did Sunstone/Verland recoup initial seed?









👍️0
Staypositive1 Staypositive1 2 years ago
might wait till .035...lol
👍️0
Phosphene Phosphene 3 years ago
IO Biotech begins trading on Nasdaq Global Market today.

IPO pps is $14.

Thu, November 4, 2021, 11:52 PM.

https://finance.yahoo.com/news/io-biotech-inc-announces-pricing-035200314.html?fr=sycsrp_catchall

Sunstone and Novo Holdings involved.
👍️0
Phosphene Phosphene 3 years ago
EXPLORATORY PROJECT TO COMPARE IO BIOTECH ANTIGENS LINKED TO MYMETICS’ (MYMX) VIROSOMES IN A PRECLINICAL TUMOR MODEL

https://www.mymetics.com/media-center/exploratory-project-compare-io-biotech-antigens-linked-mymetics-virosomes-preclinical-tumor-model/


IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

https://www.prnewswire.com/news-releases/io-biotech-announces-clinical-collaboration-with-msd-to-evaluate-io102-io103-with-keytruda-pembrolizumab-as-first-line-treatment-in-metastatic-melanoma-patients-in-a-phase-3-trial-301375679.html
👍️0
Phosphene Phosphene 3 years ago
Denmark's IO Biotech seeks $110M+ in Nasdaq debut.

https://pitchbook.com/newsletter/denmarks-io-biotech-seeks-110m-in-nasdaq-debut

https://www.fiercebiotech.com/biotech/io-biotech-raises-155m-to-trial-ido-and-pd-l1-cancer-vaccines

https://www.iobiotech.com/

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma

https://www.firstwordpharma.com/node/1783725?tsid=17
👍️0

Your Recent History

NASDAQ
IOBT
IO Biotech
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved